Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: A national cancer data base study

Journal of Clinical Oncology

Volumn 34, Issue 27, 2016, Pages 3267-3275

  Hanna, Nawar ^a   Sun, Maxine ^a   Meyer, Christian P ^a   Nguyen, Paul L ^a   Pal, Sumanta K ^b   Chang, Steven L ^a   De Velasco, Guillermo ^a   Trinh, Quoc Dien ^a   Choueiri, Toni K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE NEPHRECTOMY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; NEPHRECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; SURGICAL MORTALITY; SURVIVAL ANALYSIS; CARCINOMA, RENAL CELL; EPIDEMIOLOGY; KAPLAN MEIER METHOD; KIDNEY NEOPLASMS; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; REGISTER; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; UNITED STATES;

AGED; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEPHRECTOMY; PROPORTIONAL HAZARDS MODELS; REGISTRIES; UNITED STATES;

EID: 84984946296     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.66.7931     Document Type: Article

References (28)

1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65:5-29, 2015
2. Chow W-H, Devesa SS: Contemporary epidemiology of renal cell cancer. Cancer J 14:288-301, 2008
3. Flanigan RC, Mickisch G, Sylvester R, et al: Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis. J Urol 171:1071-1076, 2004
4. US Food and Drug Administration: Center for Drug Evaluation and Research Approval Package for Application Number NDA 21-923. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2005/021923-s000-Nexavar-Approv.pdf
5. Psutka SP, Kim SP, Gross CP, et al: The impact of targeted therapy on management of metastatic renal cell carcinoma: Trends in systemic therapy and cytoreductive nephrectomy utilization. Urology 85:442-451, 2015
6. Conti SL, Thomas I-C, Hagedorn JC, et al: Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. Int J Cancer 134:2245-2252, 2014
7. Tsao C-K, Small AC, Kates M, et al: Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: A SEER analysis. World J Urol 31:1535-1539, 2013
8. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology. Kidney Cancer. http://www.nccn.org/professionals/physician-gls/pdf/kidney.pdf
9. Winchester DP, Stewart AK, Bura C, et al: The National Cancer Data Base: A clinical surveillance and quality improvement tool. J Surg Oncol 85:1-3, 2004
10. Edge S, Byrd DR, Compton CC, et al (eds): AJCC Cancer Staging Manual (ed 7). Springer-Verlag New York, 2010
11. Smaldone MC, Handorf E, Kim SP, et al: Temporal trends and factors associated with systemic therapy after cytoreductive nephrectomy: An analysis of the National Cancer Database. J Urol 193:1108-1113, 2015
12. Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613-619, 1992
13. Estève J, Benhamou E, Raymond L: Statistical methods in cancer research. Volume IV. Descriptive epidemiology. IARC Sci Publ (128):1-302, 1994
14. Heng DYC, Wells JC, Rini BI, et al: Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 66:704-710, 2014
15. Flanigan RC, Salmon SE, Blumenstein BA, et al: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345:1655-1659, 2001
16. Mickisch GH, Garin A, van Poppel H, et al: Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: A randomised trial. Lancet 358:966-970, 2001
17. You D, Jeong IG, Song C, et al. Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era. Jpn J Clin Oncol 45:96-102, 2015
18. Mathieu R, Pignot G, Ingles A, et al: Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features. Urol Oncol 33:339.e9-339.e15, 2015
19. Choueiri TK, Xie W, Kollmannsberger C, et al: The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 185:60-66, 2011
20. Xiao W-J, Zhu Y, Dai B, et al: Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: A SEER analysis. Int Braz J Urol 41:288-295, 2015
21. Abern MR, Scosyrev E, Tsivian M, et al: Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era. Anticancer Res 34:2405-2411, 2014
22. Zini L, Capitanio U, Perrotte P, et al: Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. Urology 73:342-346, 2009
23. Gershman B, Moreira DM, Boorjian SA, et al: Comprehensive characterization of the perioperative morbidity of cytoreductive nephrectomy. Eur Urol 69:84-91, 2016
24. Jackson BL, Fowler S, Williams ST: Perioperative outcomes of cytoreductive nephrectomy in the UK in 2012. BJU Int 116:905-910, 2015
25. Trinh Q-D, Bianchi M, Hansen J, et al: Inhospital mortality and failure to rescue after cytoreductive nephrectomy. Eur Urol 63:1107-1114, 2013
26. Heng DYC, Xie W, Regan MM, et al: Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study. J Clin Oncol 27:5794-5799, 2009
27. Culp SH, Tannir NM, Abel EJ, et al: Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer 116:3378-3388, 2010
28. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00930033